期刊
NATURE MEDICINE
卷 24, 期 1, 页码 103-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4439
关键词
-
资金
- NCI [U10CA98543]
- NCI, US National Institutes of Health [HHSN261200800001E]
- Fred Hutchinson Scientific Computing
- University of Southern California's Center for High-Performance Computing
- National Science Foundation (NSF) [ACI-1341935]
- COG [U10CA98543, U10CA180886]
- COG Statistics and Data Center [U10CA098413, U10CA180899]
- COG Specimen Banking [U24CA114766, R01CA114563]
- St. Baldrick's Foundation
- Alex's Lemonade Stand
- Target Pediatric AML (TpAML) [P20GM121293]
- Arkansas Biosciences Institute
- Jane Anne Nohl Hematology Research Fund
- NATIONAL CANCER INSTITUTE [R01CA114563, P30CA021765, U10CA180899, U24CA114766, U10CA098543, U10CA180886, U10CA098413] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM121293] Funding Source: NIH RePORTER
We present the molecular landscape of pediatric acute myeloid leukemia (AML) and characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG-National Cancer Institute (NCI) TARGET AML initiative assessed cases by whole-genome, targeted DNA, mRNA and microRNA sequencing and CpG methylation profiling. Validated DNA variants corresponded to diverse, infrequent mutations, with fewer than 40 genes mutated in >2% of cases. In contrast, somatic structural variants, including new gene fusions and focal deletions of MBNL1, ZEB2 and ELF1, were disproportionately prevalent in young individuals as compared to adults. Conversely, mutations in DNMT3A and TP53, which were common in adults, were conspicuously absent from virtually all pediatric cases. New mutations in GATA2, FLT3 and CBL and recurrent mutations in MYC-ITD, NRAS, KRAS and WT1 were frequent in pediatric AML. Deletions, mutations and promoter DNA hypermethylation convergently impacted Wnt signaling, Polycomb repression, innate immune cell interactions and a cluster of zinc finger-encoding genes associated with KMT2A rearrangements. These results highlight the need for and facilitate the development of age-tailored targeted therapies for the treatment of pediatric AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据